Physician profile
Poonam Misra
NPI 1386062263
$9,863.37
in general payments reported to CMS, 2019-2025
9 companies · $5,104 in 2025
The $5,104 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $144 · 2021: $117 · 2022: $1,533 · 2023: $1,571 · 2024: $1,223 · 2025: $5,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,783 · Food and Beverage: $1,504 · Travel and Lodging: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,782.50 |
| Food and Beverage | $1,503.83 |
| Travel and Lodging | $611.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $5,941.84 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idose, Idosetr |
| Abbvie INC. | $1,476.68 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,464.84 | 2022-2024 | Vyzulta |
| Alcon Vision LLC | $720.50 | 2020-2024 | Clareon, Acrysof Iq Panoptix Uv Iol, Hydrus Microstent |
| Aerie Pharmaceuticals, INC. | $99.64 | 2021 | |
| New World Medical,INC. | $70.80 | 2022-2023 | |
| Nova Eye, INC. | $47.20 | 2023 | |
| Oyster Point Pharma, INC. | $24.38 | 2023 | Tyrvaya |
| Ivantis, INC | $17.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.